Despite short-term contraction caused by the ongoing COVID-19 pandemic, as well as delays in the availability of new technologies due to strict regulations and the use of alternative treatments, the Japanese market for interventional oncology devices will grow moderately over the forecast period due to an expanding patient pool, the increasing adoption of minimally invasive techniques, and the introduction and adoption of premium-priced devices.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for interventional oncology devices in the US across a 10-year period.
The COVID-19 pandemic will affect the interventional oncology device market in the short term.
How will COVID-19 affect procedure volumes?
What impact will the pandemic have on market dynamics?
Alternative forms of treatment are commonly used to treat cancer in Japan.
What alternatives compete with interventional oncology devices?
What impact will these treatments have on the interventional oncology device market?
Gelatin sponges represent a large portion of the Japanese embolization device market.
What factors will contribute to the adoption of different embolization particles for the treatment of both primary and secondary liver cancer?
Which companies represent the major players in the embolization device market?
Radioembolization spheres have not yet been approved in Japan.
When are radioembolization spheres expected to be launched in Japan?
What impact will the launch of these devices have on the overall market?
- Interventional Oncology Devices - Market Insights - Japan
Author(s): Pankhil Gandhi, PharmD
Pankhil Gandhi is a research associate within the Cardiovascular Medtech Insights team at Decision Resources Group, specializing in transcatheter embolization and occlusion devices and deep venous disease treatment devices markets. Pankhil holds a Doctor of Pharmacy degree from the Babasaheb Ambedkar Marathwada University, Aurangabad.